Efficacy of combined androgen blockade with zoledronic acid treatment in prostate cancer with bone metastasis: The ZABTON-PC (zoledronic acid/androgen blockade trial on prostate cancer) study

Anticancer Research

Volumn 33, Issue 9, 2013, Pages 3837-3844

  Ueno, Satoru ^a   Mizokami, Atsushi ^a   Fukagai, Takashi ^b   Fujimoto, Naohiro ^c   Oh Oka, Hitoshi ^d   Kondo, Yukihiro ^e   Arai, Gaku ^f   Ide, Hisamitsu ^g   Horie, Shigeo ^g   Ueki, Osamu ^h   Kawaguchi, Kouhei ^h   Shimamura, Masayoshi ⁱ   Orito, Matsuo ^j   Ishida, Takeyuki ^k   Ikeda, Daisuke ^l   Namiki, Mikio ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^b SHOWA UNIVERSITY   (Japan)

^c UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^d Graduate School of Health Sciences   (Japan)

^e NIPPON MEDICAL SCHOOL   (Japan)

^f DOKKYO MEDICAL UNIVERSITY   (Japan)

^g TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h Noto General Hospital   (Japan)

ⁱ ISHIKAWA PREFECTURAL CENTRAL HOSPITAL   (Japan)

^j Kanazawa Social Insurance Hospital   (Japan)

^k Saiseikai Takaoka Hospital   (Japan)

^l Kouseiren Takaoka Hospital   (Japan)

more..

Author keywords

Bone metastasis; Combined androgen blockade; Prostate cancer; Zoledronic acid

Indexed keywords

BICALUTAMIDE; FLUTAMIDE; PROSTATE SPECIFIC ANTIGEN; ZOLEDRONIC ACID;

ADULT; ADVERSE OUTCOME; AGED; ANTIANDROGEN THERAPY; ARTICLE; BONE METASTASIS; BONE PAIN; CANCER SURVIVAL; CASTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLEASON SCORE; HUMAN; HUMAN TISSUE; MULTICENTER STUDY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

BONE METASTASIS; COMBINED ANDROGEN BLOCKADE; PROSTATE CANCER; ZOLEDRONIC ACID;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; DIPHOSPHONATES; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS;

EID: 84884999951     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Akaza H, Hinotsu S, Usami M, Arai Y, Kanetake H, Naito S and Hirao Y: Combined androgen blockade with bicalutamide for advanced prostate cancer: Long-term follow-up of a phase III, double-blind, randomized study for survival. Cancer 115: 3437-3445, 2009.
2. Suzuki H, Okihara K, Miyake H, Fujisawa M, Miyoshi S, Matsumoto T, Fujii M, Takihana Y, Usui T, Matsuda T, Ozono S, Kumon H, Ichikawa T and Miki T: Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. J Urol 180: 921-927, 2008.
3. Narimoto K, Mizokami A, Izumi K, Mihara S, Sawada K, Sugata T, Shimamura M, Miyazaki K, Nishino A and Namiki M: Adrenal androgen levels as predictors of outcome in castrationresistant prostate cancer patients treated with combined androgen blockade using flutamide as a second-line anti-androgen. Int J Urol 17: 337-345, 2010.
4. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA and Zheng M: Longterm efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96: 879-882, 2004.
5. Coleman RE: Bisphosphonates: Clinical experience. Oncologist 9(Suppl 4): 14-27, 2004.
6. Saad F: Zoledronic acid significantly reduces pathologic fractures in patients with advanced-stage prostate cancer metastatic to bone. Clin Prostate Cancer 1: 145-152, 2002.
7. Saad F: New research findings on zoledronic acid: Survival, pain, and anti-tumour effects. Cancer treatment reviews 34: 183-192, 2008.
8. Lipton A, Colombo-Berra A, Bukowski RM, Rosen L, Zheng M, and Urbanowitz G: Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid. Clin Cancer Res 10: 6397S-6403S, 2004.
9. Lipton A, Cook R, Saad F, Major P, Garnero P, Terpos E, Brown JE and Coleman RE: Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 113: 193-201, 2008.
10. Coleman RE: Emerging strategies in bone health management for the adjuvant patient. Semin Oncol 34: S11-16, 2007.
11. Asahi H, Mizokami A, Miwa S, Keller ET, Koshida K and Namiki M: Bisphosphonate induces apoptosis and inhibits proosteoclastic gene expression in prostate cancer cells. Int J Urol 13: 593-600, 2006.
12. Miwa S, Mizokami A, Keller ET, Taichman R, Zhang J and Namiki M: The bisphosphonate YM529 inhibits osteolytic and osteoblastic changes and CXCR-4-induced invasion in prostate cancer. Cancer Res 65: 8818-8825, 2005.
13. Soloway MS, Hardeman SW, Hickey D, Raymond J, Todd B, Soloway S and Moinuddin M: Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 61: 195-202, 1988.
14. Bertelli G, Heouaine A, Arena G, Botto A, Garrone O, Colantonio I, Occelli M, Fea E, Giubergia S and Merlano M: Weekly docetaxel and zoledronic acid every four weeks in hormone-refractory prostate cancer patients. Cancer Chemother Pharmacol 57: 46-51, 2006.
15. Kamiya N, Suzuki H, Endo T, Takano M, Yano M, Naoi M, Nishimi D, Kawamura K, Imamoto T and Ichikawa T: Additive effect of zoledronic acid on serum prostate-specific antigen changes for hormone-sensitive prostate cancer patients with bone metastasis treated by combined androgen blockade. Int J Urol 19: 169-173, 2012.
16. Uemura H, Yanagisawa M, Ikeda I, Fujinami K, Iwasaki A, Noguchi S, Noguchi K and Kubota Y: Possible antitumor activity of initial treatment with zoledronic acid with hormonal therapy for bone-metastatic prostate cancer in multicenter clinical trial. Int J Clin Oncol 18: 472-477, 2013.
17. Giraudo E, Inoue M and Hanahan D: An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 114: 623-633, 2004.
18. Boissier S, Ferreras M, Peyruchaud O, Magnetto S, Ebetino FH, Colombel M, Delmas P, Delaisse JM and Clezardin P: Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 60: 2949-2954, 2000.
19. Asahi H, Mizokami A, Maeda Y, Komatsu K, Koshida K and Namiki M: Bisphosphonate therapy for hormone refractory prostate cancer with bone metastasis. J Urol 169: 281-282, 2003.
20. Miwa S, Mizokami A, Konaka H, Izumi K, Nohara T and Namiki M: A case of bone, lung, pleural and liver metastases from renal cell carcinoma which responded remarkably well to zoledronic acid monotherapy. Jpn J Clin Oncol 39: 745-750, 2009.
21. Gnant M: Zoledronic acid in the treatment of early-stage breast cancer: Is there a final verdict? Curr Oncol Rep 14: 35-43, 2012.
22. Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Postlberger S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic-Radisic V, Samonigg H, Tausch C, Eidtmann H, Steger G, Kwasny W, Dubsky P, Fridrik M, Fitzal F, Stierer M, Rucklinger E, Greil R and Marth C: Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J M 360: 679-691, 2009.
23. Vogel CL, Yanagihara RH, Wood AJ, Schnell FM, Henderson C, Kaplan BH, Purdy MH, Orlowski R, Decker JL, Lacerna L and Hohneker JA: Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy. Oncologist 9: 687-695, 2004.